We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register to chat with like-minded investors on our interactive forums.
| Share Name | Share Symbol | Market | Type |
|---|---|---|---|
| Nucryst Pharmaceuticals - Common Shares (MM) | NASDAQ:NCST | NASDAQ | Common Stock |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| 0.00 | 0.00% | 1.77 | 0 | 01:00:00 |
From Jul 2019 to Jul 2024
Smith & Nephew PLC (SN.LN) said Wednesday its advanced wound management unit has signed a definitive agreement to buy most of the assets of Nucryst Pharmaceuticals Corp. (NCS.T) for an initial $21 million, to be adjusted at closing for working capital changes.
MAIN FACTS:
-Smith & Nephew will acquire the manufacturing assets from Nucryst's Fort Saskatchewan, Canada operations and the intellectual property estate.
-Terms of acquisition are pending approval by Nucryst shareholders and the transaction is anticipated to close before the end of the year.
-By London Bureau, Dow Jones Newswires; Contact Ian Walker; +44 (0)20 7842 9296; ian.walker@dowjones.com
1 Year Nucryst Chart |
1 Month Nucryst Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
